Gene Therapy Institute

Check out the latest Ohio State 2024 Research Commercial that highlights several of our gene therapy researchers below! Featuring Drs. Kristy Townsend, Sayoko Moroi, Higuita-Castro and Gallego-Perez 😀 📽 https://go.osu.edu/CvRx

Hear from Tom Mendel, MD, PhD on his gene therapy research goals for inherited retinal diseases 👁️🧬

In an interview with Check Rare James “Brad” Elder, MD, Director of Neurosurgical Oncology at the Ohio State University Comprehensive Cancer Center, discusses a clinical trial evaluating the investigational gene therapy, AVB-101 in patients with frontotemporal dementia (FTD). Learn more and watch the interview here: https://go.osu.edu/CuJk

Congratulations to Dr. Victor Van Laar in the Lonser Lab, who received an Ohio State ERIK President’s Research Excellence Program Accelerator Grant! Project Title: Utilizing a mitochondria-targeting small molecule as a therapeutic for neuronal restoration and protection in neurodegenerative disease Project description: There is a clinical need for a disease-altering therapy in neurodegenerative Parkinson's that can address disease throughout the body. This team has identified a potential candidate, a small molecule that targets the mitochondria that exhibits neuroprotective properties, that will be evaluated. https://go.osu.edu/CskN

Congratulations to Natalia Higuita-Castro, PhD, who appointed to serve as a standing member of the NIH Drug and Biologic Therapeutic Delivery (DBTD) study section! Dr. Higuita-Castro was nominated to be a standing member because of her demonstrated competence and achievement in her scientific discipline as evidenced by the quality of her research accomplishments, publications in scientific journals, and other significant scientific activities, achievements, and honors. go.osu.edu/CsQ5

AviadoBio has launched its Phase I/II ASPIRE-FTD clinical trial at the Ohio State University. This study will evaluate investigational gene therapy AVB-101 in people with frontotemporal dementia with progranulin gene mutations. Learn more: https://go.osu.edu/CsCp

The Lonser Lab is #hiring 2 research associate 1 positions to participate in planning, design, execution, and management of all in-vivo research studies. Learn more and apply here 👇 https://go.osu.edu/CrsS

The Lonser Lab is #hiring 2 research aide positions to provide basic and general assistance to research projects. Learn more and apply here: https://go.osu.edu/CrkB

GTI Director Russell R. Lonser, M.D. recently discussed the key challenges in optimizing gene therapy for Parkinson's Disease, particularly regarding target selection and gene choice, with NeurologyLive. Check out the article below: https://go.osu.edu/CrRc

With targeted delivery of gene therapy to specific areas of the brain using real-time MRI, researchers at The Ohio State University Gene Therapy Institute in Columbus are exploring avenues to improve the lives of patients with Alzheimer's and Parkinson's diseases, brain tumors and other neurodegenerative disorders. "The recent refinements in gene therapy have allowed for an increase in disorders to be treated," said Dr. Russell Lonser, chair of the department of neurological surgery and director of the Gene Therapy Institute. At Ohio State, "clinical trials are going to use gene therapy for treatment of epilepsy and ALS," he said. https://go.osu.edu/CrGN